Drugs / Ac225-DOTA-M5A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05204147 | Jun 2022 → Jul 2026 overdue | cancer of unknown primary site, metastatic malignant neoplasm in the colon | City of Hope Medical Center | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ac225-DOTA-M5A | “This phase I study tests the safety, side effects, and best dose of Ac225-DOTA-M5A in treating patients with CEA positive colorectal cancer that has spread to other places in...” NCT05204147 ↗ |
| Action | Deplete | “delivers actinium 225 to kill them.” NCT05204147 ↗ |
| Modality | Monoclonal antibody | “Ac225-DOTA-M5A is a humanized monoclonal anti-CEA antibody” NCT05204147 ↗ |
| Route | Intravenous | “Patients receive Ac225-DOTA-M5A intravenously (IV) over 25 minutes on day 1.” NCT05204147 ↗ |